Clinical and Translational Radiation Oncology最新文献

{"title":"Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome","authors":"Kerstin Clasen ,&nbsp;Nadja Ballin ,&nbsp;Leon Schütz ,&nbsp;Irina Bonzheim ,&nbsp;Olga Kelemen ,&nbsp;Michael Orth ,&nbsp;Cihan Gani ,&nbsp;Olaf Rieß ,&nbsp;Stephan Ossowski ,&nbsp;Maximilian Niyazi ,&nbsp;Christopher Schroeder","doi":"10.1016/j.ctro.2024.100894","DOIUrl":"10.1016/j.ctro.2024.100894","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Neoadjuvant chemoradiotherapy (NCRT) is a standard treatment option for locally advanced rectal cancer. However, there is still conflicting data about the genetic landscape and potential dynamics during and after NCRT. This study evaluated oncogenic driver mutations before NCRT and investigated corresponding resection samples after treatment.</div></div><div><h3>Materials and methods</h3><div>In 17 patients the pre-therapeutic biopsy and in ten cases the related resection specimen were investigated by next-generation sequencing using a dedicated cancer panel (708 genes). Oncogenic driver mutations and tumor mutational burden (TMB) were compared pre- and post NCRT to evaluate stability of the genomic landscape. TMB and frequently detected driver mutations were correlated with outcome parameters.</div></div><div><h3>Results</h3><div>In our corresponding tumor samples before and after NCRT 95.2 % of the oncogenic driver mutations could be found in both specimens whereas one <em>ATM</em> and one <em>RYR1</em> mutation were not detectable after NCRT. TMB decreased in all patients after neoadjuvant treatment. <em>KRAS</em> ± <em>TP53</em> mutations and TMB ≥ 5 were associated with impaired outcome.</div></div><div><h3>Conclusion</h3><div>Most oncogenic driver mutations investigated persisted after neoadjuvant treatment. At the same time, we did not observe ascending TMB after treatment but decline. Thus, NCRT does not seem to induce a relevant number of new driver mutations or mutational burden. Genetic profiling implies the potential to support tumor-informed approaches and outcome estimation in future.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100894"},"PeriodicalIF":2.7,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142722738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic ablative radiotherapy for primary kidney cancer – An international patterns of practice survey","authors":"Katherine Taplin ,&nbsp;Raquibul Hannan ,&nbsp;Simon S. Lo ,&nbsp;Scott C. Morgan ,&nbsp;Muhammad Ali ,&nbsp;Samantha Sigurdson ,&nbsp;Matthias Guckenberger ,&nbsp;Anand Swaminath","doi":"10.1016/j.ctro.2024.100891","DOIUrl":"10.1016/j.ctro.2024.100891","url":null,"abstract":"<div><h3>Purpose</h3><div>To conduct an international survey of radiation oncologists treating primary renal cell carcinoma (RCC) with SABR to ascertain the general patterns of SABR use, common dose/treatment/follow-up details, and expected outcomes.</div></div><div><h3>Materials and methods</h3><div>A 51-question survey was created containing the following themes: prevalence and clinical scenarios in which RCC SABR is used, dose-fractionation schedules, treatment delivery details, follow-up/outcome assessments, and implementation barriers. The survey was distributed widely across multiple influential radiation oncology societies and social media, and ran from January to April 2023.</div></div><div><h3>Results</h3><div>A total of 255 respondents participated, mostly from academic centers within Europe/North America. Of these, 40 % (n = 102) currently offer SABR (50 % having begun within the last 3 years). Common barriers in non-users included lack of referrals by urologists and lack of supportive practice guidelines. Of respondents who do offer SABR, 77 % treat both small (4 cm or less) and large (&gt;4 cm) renal masses. Dose-fractionation strategies varied from 27-52 Gy (3–5 fractions) for multifraction regimens, and 15–34 Gy for single fractions. Apart from treatment for medically inoperable disease, scenarios in which SABR was likely to be offered were for recurrence post surgery/thermal ablation and for oligometastatic kidney lesions. Uncommon scenarios included RCC with renal vein/inferior vena cava thrombosis, and as cytoreductive therapy in metastatic RCC. Expected local control outcomes were generally above 70 %, higher for small versus large renal masses.</div></div><div><h3>Conclusions</h3><div>SABR is a relatively newer indication for primary RCC, offered by less than 50% of respondents, with both consistent and variable practice patterns observed.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100891"},"PeriodicalIF":2.7,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fractionated stereotactic radiotherapy of brainstem metastases – Clinical outcome and prognostic factors","authors":"Anna Krämer ,&nbsp;Laura Hahnemann ,&nbsp;Fabian Schunn ,&nbsp;Christoph A. Grott ,&nbsp;Michael Thomas ,&nbsp;Petros Christopoulos ,&nbsp;Jonathan W. Lischalk ,&nbsp;Juliane Hörner-Rieber ,&nbsp;Philipp Hoegen-Saßmannshausen ,&nbsp;Tanja Eichkorn ,&nbsp;Maximilian Y. Deng ,&nbsp;Eva Meixner ,&nbsp;Kristin Lang ,&nbsp;Angela Paul ,&nbsp;Fabian Weykamp ,&nbsp;Jürgen Debus ,&nbsp;Laila König","doi":"10.1016/j.ctro.2024.100893","DOIUrl":"10.1016/j.ctro.2024.100893","url":null,"abstract":"<div><h3>Introduction</h3><div>Brain metastases (BM) are the most common malignancy in the central nervous system (CNS) and observed in approximately 30% of cancer patients. Brainstem metastases (BSM) are challenging because of their location and the associated neurological risks. There are still no general therapeutic recommendations in this setting. Stereotactic radiosurgery (SRS) is one of few possible local therapy options but limited due to the tolerance dose of the brainstem. There is still no standard regarding the optimal dose und fractionation.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 65 patients with fractionated stereotactic radiotherapy (fSRT) for 69 BSM. FSRT was delivered at a dose of 30 Gy in six fractions prescribed to the 70 % isodose performed with Cyberknife. Overall survival (OS), local control (LC) and total intracranial brain control (TIBC) were analyzed via Kaplan-Meier method. Cox proportional hazards models were used to identify prognostic factors.</div></div><div><h3>Results</h3><div>Median follow-up was 27.3 months. One-year TIBC was 35.0 % and one-year LC was 84.1 %. Median OS was 8.9 months. In total, local progression occurred in 7.7 % and in 8.2 % symptomatic radiation-induced contrast enhancements (RICE) were diagnosed. In univariate analysis the Karnofsky performance scale index (KPI) (p = 0,001) was an independent prognostic factor for longer OS. Acute CTCAE grade 3 toxicities occurred in 18.4 %.</div></div><div><h3>Conclusion</h3><div>FSRT for BSM is as an effective and safe treatment approach with high LC rates and reasonable neurological toxicity despite the poor prognosis in this patient cohort is still very poor. Clinical and imaging follow-up is necessary to identify cerebral progression and adverse toxicity including RICE.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100893"},"PeriodicalIF":2.7,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiation therapy in primary liver tumor: Local control, outcomes and toxicities","authors":"Ludovic Hernandez ,&nbsp;Laure Parent ,&nbsp;Victoire Molinier ,&nbsp;Bertrand Suc ,&nbsp;Françoise Izar ,&nbsp;Elisabeth Moyal ,&nbsp;Jean-Marie Peron ,&nbsp;Philippe Otal ,&nbsp;Amélie Lusque ,&nbsp;Anouchka Modesto","doi":"10.1016/j.ctro.2024.100892","DOIUrl":"10.1016/j.ctro.2024.100892","url":null,"abstract":"<div><h3>Objective</h3><div>Stereotactic body radiation therapy (SBRT) is a therapeutic option in the guidelines for liver primaries after standard strategies like surgery or thermoablation have failed. To assess its efficacy and safety, we reviewed all patients treated by SBRT for a hepatocellular carcinoma (HCC) over a six-year period.</div></div><div><h3>Methods and materials</h3><div>The study included all patients treated by SBRT for HCC between April 2015 and November 2021 in the University Cancer Institute at Toulouse-Oncopole. All patients were inoperable and not eligible for thermoablation, or after a failure. All tumor sizes were included and cirrhosis up to Child-Pugh B was accepted. Local control (LC), overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Treatment response was assessed using mRECIST criteria. Toxicity was graded using CTCAE (v4.0).</div></div><div><h3>Results</h3><div>One hundred and nine patients with 118 lesions were treated. Half underwent prior standard treatment. Median dose was 50 Grays in five fractions for most patients. Chronic liver disease represented 90.8 % of cases with a median age of 69 years. Median tumor size was 4.0 cm. Median follow-up was 22.2 months [95 %CI: 15.1–30.4]. LC, OS and PFS at two years were 82.4 % [95 %CI: 71.3; 89.5], 73.2 % [95 %CI: 61.5; 81.8] and 35.8 % [95 %CI: 25.1; 46.7], respectively. Acute toxicities occurred in 20.2 % of patients, including 10.1 % grade 3–4 and 1.8 % grade 5. Late toxicities occurred in 5.5 % of patients including 4.6 % grade 3–4. Grade ≥ 3 toxicity was related to digestive perforation or liver failure.</div></div><div><h3>Conclusion</h3><div>SBRT provides good LC with an acceptable safety profile. It can be used in several settings such as salvage therapy or in combination with validated treatment. Prospective randomized trials are needed to validate SBRT as a standard alternative.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100892"},"PeriodicalIF":2.7,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is postoperative radiotherapy effective in patients with completely resected pathologic stage IIIA(N2) non-small cell lung cancer? High-risk populations should consider it","authors":"Shu-Xian Zhang ,&nbsp;Chen-Chen Zhang ,&nbsp;Run-Ping Hou ,&nbsp;Xu-Wei Cai ,&nbsp;Jun Liu ,&nbsp;Wen Yu ,&nbsp;Qin Zhang ,&nbsp;Jin-Dong Guo ,&nbsp;Chang-Lu Wang ,&nbsp;Hong-Xuan Li ,&nbsp;Zheng-Fei Zhu ,&nbsp;Xiao-Long Fu ,&nbsp;Wen Feng","doi":"10.1016/j.ctro.2024.100889","DOIUrl":"10.1016/j.ctro.2024.100889","url":null,"abstract":"<div><h3>Background and purpose</h3><div>We aimed to assess the benefits of postoperative radiotherapy (PORT) in completely resected patients with pathologic stage IIIA(N2) non-small cell lung cancer (NSCLC) with a high risk of locoregional recurrence (LRR).</div></div><div><h3>Materials and methods</h3><div>A prospective, randomized trial was conducted starting in July 2016 to explore the optimal timing of PORT in high-LRR-risk patients with completely resected IIIA(N2) NSCLC (NCT02974426). Patients were identified as high-LRR-risk patients via the prognostic index (PI) model and were randomly assigned to PORT-first or PORT-last treatment. To evaluate PORT for high-LRR-risk patients, all patients in this trial constituted the PORT cohort, whereas high-LRR-risk patients without PORT were selected from a retrospective cohort as the non-PORT cohort. Propensity score-matched (PSM) analyses were conducted to compare overall survival (OS), disease-free survival (DFS), locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS).</div></div><div><h3>Results</h3><div>Between 2016 and 2022, 132 patients were included in the trial, with a median follow-up of 49.3 months. The 3-year OS rate was 83.2 %, and the 3-year DFS rate was 35.0 %. Among these patients, 122 patients (92 %) received planned PORT. For 132 intention-to-treat patients, PSM analysis with the non-PORT cohort (n = 307) resulted in 130 matched pairs. The results revealed that PORT improved LRFS (3-year LRFS, 77.6 % vs. 57.3 %; p = 0.00014), DFS (3-year DFS, 35.2 % vs. 28.6 %; p = 0.038), and OS (3-year OS, 83.0 % vs. 60.7 %; p = 0.00017), with no difference in DMFS (p = 0.17).</div></div><div><h3>Conclusion</h3><div>PORT could increase local control, DFS, and OS in high-LRR-risk patients with completely resected IIIA(N2) NSCLC. Future research should utilize multidimensional data to pinpoint more precise subgroups benefiting from PORT, with prospective trials validating these findings.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100889"},"PeriodicalIF":2.7,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Timeline of cognitive impairments after radiotherapy for head and neck cancer: A review","authors":"K. Wickborn ,&nbsp;C.W.J. van der Weijden ,&nbsp;E.F.J. de Vries ,&nbsp;T.W.H. Meijer ,&nbsp;M.C.A. Kramer ,&nbsp;J.M. Spikman ,&nbsp;A.M. Buunk ,&nbsp;A. van der Hoorn","doi":"10.1016/j.ctro.2024.100890","DOIUrl":"10.1016/j.ctro.2024.100890","url":null,"abstract":"<div><h3>Background</h3><div>With advances in cancer treatments, long-term impairments of survivors have become more apparent. Radiotherapy of tumors in or near the brain can potentially induce cognitive impairments, impacting the quality of life of survivors. Currently, there is a lack of comprehensive information on the timeline of cognitive impairments following radiotherapy for head and neck cancer (HNC). To address this gap, we conducted a literature review on cognitive impairments observed after radiotherapy for HNC.</div></div><div><h3>Methods</h3><div>The literature review was conducted using PubMed, Web of Science, PsycINFO, and Google Scholar. Search terms included the following keywords: head and neck tumors, radiotherapy, treatment responses, cognitive impairments, as well as variants and related subcategories.</div></div><div><h3>Result</h3><div>Our review encompassed 23 studies involving a total of 1059 HNC patients, predominantly nasopharyngeal carcinoma. Overall, studies indicated a decline in cognitive performance post-radiotherapy compared to baseline scores, control groups, or normative data. The literature on acute effects is scarce and studies with complete neuropsychological assessments are missing. Cognitive impairments were prevalent in the majority of patients at six to 12 months post-radiotherapy, with memory deficits being the most prominent. Long-term assessments demonstrated that these cognitive deficits persisted even beyond seven years, suggesting a potentially irreversible decline in cognition following radiotherapy.</div></div><div><h3>Conclusion</h3><div>Cognitive impairments are frequently observed at least six months after radiotherapy. Standardized cognitive assessments are imperative to evaluate impairments in individual patients. Future research in HNC should integrate neuropsychological evaluations to enhance our understanding of domain-specific impairments and the complete timeline of cognitive changes after radiotherapy.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"52 ","pages":"Article 100890"},"PeriodicalIF":2.7,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143171156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elective pelvic nodal irradiation in elderly men treated with hypofractionated radiotherapy","authors":"Rachel M. Glicksman ,&nbsp;Andrew Loblaw ,&nbsp;Patrick Cheung","doi":"10.1016/j.ctro.2024.100888","DOIUrl":"10.1016/j.ctro.2024.100888","url":null,"abstract":"","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100888"},"PeriodicalIF":2.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic utility of IGF-1 in hepatocellular carcinoma treated with stereotactic body radiotherapy","authors":"Ahmed Allam Mohamed ,&nbsp;Cennet Sahin ,&nbsp;Marie-Luise Berres ,&nbsp;Oliver Beetz ,&nbsp;Martin von Websky ,&nbsp;Thomas Vogel ,&nbsp;Florian W.R. Vondran ,&nbsp;Philipp Bruners ,&nbsp;Matthias Imöhl ,&nbsp;Katharina Frank ,&nbsp;Edith Vogt ,&nbsp;Binney Pal Singh ,&nbsp;Michael J. Eble","doi":"10.1016/j.ctro.2024.100887","DOIUrl":"10.1016/j.ctro.2024.100887","url":null,"abstract":"<div><h3>Background</h3><div>Hepatocellular carcinoma (HCC) poses a significant challenge for patients ineligible for surgical resection or liver transplantation. Local therapies like Stereotactic Body Radiotherapy (SBRT) are crucial for those with liver-limited disease. Insulin-like growth factor-1 (IGF-1) is a potential biomarker for liver function. This study evaluates IGF-1’s prognostic value in predicting survival outcomes in HCC patients undergoing SBRT.</div></div><div><h3>Methods</h3><div>We analyzed 42 HCC patients treated with SBRT between May 2021 and January 2024, with IGF-1 levels measured within four weeks before SBRT. Patient demographics, tumor metrics, and clinical outcomes were examined. The prognostic significance of IGF-1 was assessed using Cox proportional hazards and ROC curve analysis to determine optimal IGF-1 cutoffs for survival prediction. A nomogram predicting 1-year and 2-year survival was constructed using a multivariate Cox model.</div></div><div><h3>Results</h3><div>IGF-1 levels were significantly lower in patients with cirrhosis or sarcopenia. Median overall survival (OS) was 24 months, with a significant survival difference favoring patients with IGF-1 levels above 62.4 ng/ml (Hazard Ratio [HR]: 5.9, P = 0.0025). A multivariable Cox model including Child-Turcotte-Pugh (CTP) score, IGF-1, and tumor volume effectively predicted survival. IGF-1 and tumor volume significantly impacted OS (HR: 6.9 and 1.004, p = 0.014 and 0.0022, respectively). Integrating IGF-1 with CTP score improved predictive accuracy (c-index 0.66 to 0.75, p = 0.052).</div><div>The nomogram, integrating IGF-1 with the CTP and tumour volume, exhibited robust predictive accuracy with an area under the curve (AUC) of 0.84 for 2-year survival.</div></div><div><h3>Conclusion</h3><div>IGF-1 is a reliable biomarker for liver function and survival prediction in HCC patients undergoing SBRT. Higher IGF-1 levels indicate better prognosis. The developed nomogram, incorporating IGF-1, enhances clinical decision-making for SBRT management. Further validation in larger cohorts is needed.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100887"},"PeriodicalIF":2.7,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142652596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Normal tissue complication probability modeling for late rectal bleeding after conventional or hypofractionated radiotherapy for prostate cancer","authors":"Christian A.M. Jongen ,&nbsp;Ben J.M. Heijmen ,&nbsp;Wilco Schillemans ,&nbsp;Andras Zolnay ,&nbsp;Marnix G. Witte ,&nbsp;Floris J. Pos ,&nbsp;Ben Vanneste ,&nbsp;Ludwig J. Dubois ,&nbsp;David van Klaveren ,&nbsp;Luca Incrocci ,&nbsp;Wilma D. Heemsbergen","doi":"10.1016/j.ctro.2024.100886","DOIUrl":"10.1016/j.ctro.2024.100886","url":null,"abstract":"<div><h3>Purpose</h3><div>To develop a single NTCP model for grade ≥ 2 late rectal bleeding (G2 LRB) after conventional or hypofractionated radiotherapy for prostate cancer.</div></div><div><h3>Methods and Materials</h3><div>The development dataset consisted of prostate cancer patients (n = 656) previously randomized to conventional (39 x 2 Gy) or hypofractionated (19 x 3.4 Gy) external beam radiotherapy with N = 89 G2 LRB cases. Candidate predictors were obtained from literature. We fitted five separate logistic regression models to the data, each with one of the following dose parameters as candidate predictors in biological effective dose (BED), assuming α/β = 3 Gy: Equivalent uniform dose (EUD) with n = 0.1, EUD with n = 0.2, the relative volume receiving ≥ 111.9 Gy in BED (V111.9, the equivalent of physical V70 for a conventional schedule), minimum BED to the hottest 0.1 cm³ (D_0.1cm3) or 2 cm³ (D_2cm3). Previous abdominal surgery was included in every model and fractionation schedule was tested as predictor in each model. A sensitivity analysis was performed by varying the α/β-ratio, n and dose-volume cutoff.</div></div><div><h3>Results</h3><div>The pre-selected candidate dosimetric predictor and previous abdominal surgery were significantly associated with the outcome in all five models. Fractionation schedule was eliminated by the backward scheme in only the EUD (n = 0.1), D_0.1cm3 and D_2cm3-based models. In internal validation these models showed AUC’s of 0.64, 0.60 &amp; 0.62, respectively. The sensitivity analyses showed that EUD models with n ≥ 0.15 and / or α/β ≥ 4 Gy failed, and EUD models based on α/β = 2 Gy with n = 0.05–0.2 showed good fits as well.</div></div><div><h3>Conclusions</h3><div>Our trial data set with different fractionation schedules offered the unique possibility to generate unbiased BED-based models. EUD (n = 0.1), D_0.1cm3 and D_2cm3 performed overall best in predicting G2 LRB; with α/β = 2 Gy equally good models were obtained. External validation is required to confirm our results.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100886"},"PeriodicalIF":2.7,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiobiology and modelling in Brachytherapy: A review inspired by the ESTRO Brachytherapy pre-meeting course","authors":"A.J. Stewart ,&nbsp;C. Chargari ,&nbsp;A. Chyrek ,&nbsp;F. Eckert ,&nbsp;J.L. Guinot ,&nbsp;T.P. Hellebust ,&nbsp;P. Hoskin ,&nbsp;C. Kirisits ,&nbsp;B. Pieters ,&nbsp;F.A. Siebert ,&nbsp;L. Tagliaferri ,&nbsp;K. Tanderup ,&nbsp;D. Todor ,&nbsp;P. Wojcieszek ,&nbsp;J.M. Hannoun-Levi","doi":"10.1016/j.ctro.2024.100885","DOIUrl":"10.1016/j.ctro.2024.100885","url":null,"abstract":"<div><div>Brachytherapy (BT) plays a key role in cancer treatment by delivering a high dose to a small volume over a short time. The use of BT is currently validated in a wide range of cancers such as cervical, prostate and breast cancers while being a favourable choice for organ preservation, such as in penile or rectal cancer, or in the setting of reirradiation. Consideration of the radiobiology of BT is integral to the choices made around dose and fractionation and combination with other techniques such as external beam radiotherapy (EBRT). Much of the radiobiology of brachytherapy is based on historic data, but fortunately there is a drive to integrate translational research including radiobiologic parameters into modern BT research. In a changing therapeutic landscape moving to a high dose rate (HDR) based on high dose per fraction, it is important to ensure that the incorporation of new radiobiology knowledge helps to drive clinical practice.</div><div>This manuscript takes the ESTRO Brachytherapy pre-meeting course (May 3, 2024 - Glasgow ESTRO meeting) as a base and develops the concepts to present an overview of radiobiology in brachytherapy. Presented are 3 different considerations: the fundamentals of BT radiobiology (BT radiobiology history, biology and BT, α/β and re-irradiation), the pre-clinical radiobiology approach (pulsed dose radiotherapy (PDR) vs HDR, BT vs best EBRT techniques, high dose regions and integrated boost) and clinical radiobiology approaches (optimal number of BT fractions, radiobiology in BR for cervical, prostate, breast, skin/H&amp;N and gastro-intestinal cancers). Presented is an analysis of radiobiology and modelling in BT aiding the integration of scientific pre-clinical and clinical data to allow a better understanding of the use of radioactive sources for cancer treatment.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100885"},"PeriodicalIF":2.7,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142722739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}